Articles Tagged: Dugs and Medication
November 1, 2013 | Category: News
Drug Delivery: Overactive immune cells swallow Trojan horse nanoparticles that carry anti-inflammatory drugs
The human immune system can be an overenthusiastic caregiver. In a spinal cord wound, immune cells often aggravate the injury by stirring up inflammation long after it’s needed, which hinders healing. Now a group of Italian researchers demonstrate that, in mice, they can quiet the cells responsible for chronic inflammation around the spinal cord by targeting them directly with drug-laden nanoparticles Continue Reading »
October 2, 2013 | Category: News
NEWARK, Calif., Oct. 2, 2013 (GLOBE NEWSWIRE) — StemCells, Inc. (Nasdaq:STEM) announced today that the U.S. Food and Drug Administration (FDA) has authorized the Company’s Investigational New Drug (IND) application for clinical testing of the Company’s proprietary HuCNS-SC® human neural stem cells as a treatment for spinal cord injury. As a first action under this IND, the Company is working to open U.S. sites for its Phase I/II clinical trial for chronic spinal cord injury, which is currently underway in Switzerland and Canada. Continue Reading »
July 1, 2011 | Category: News
Today Hawthorne, NY-based Acorda Therapeutics (NASDAQ: ACOR) announced that it licensed an experimental compound to treat spinal cord injury from medical-device giant Medtronic (NYSE: MDT). Acorda paid $3 million up front for worldwide rights to the compound, and pledged up to $32 million in regulatory and development milestone payments to Medtronic, which is based in Minneapolis. Medtronic will also receive a “single digit” percentage royalty if the product is commercialized, Acorda says. Continue Reading »
January 15, 2010 | Category: News
A breakthrough discovery by scientists at the University of Kentucky could someday lead to new treatments for a variety of diseases of the brain, spinal cord and the eye. Researchers led by Royce Mohan, associate professor of ophthalmology and visual science in the UK College of Medicine, found that the small molecule withaferin A can simultaneously target two key proteins — vimentin and glial fibrillary acidic protein (GFAP) — implicated in a damaging biological process called reactive gliosis. Continue Reading »
October 18, 2009 | Category: News
CHICAGO, Oct 18 (Reuters) – A common antidepressant combined with an intensive treadmill training program helped people with partial spinal cord injuries walk better and faster, U.S. researchers said on Sunday.
They said Forest Laboratories’ antidepressant Lexapro or escitalopram, which affects a message-carrying brain chemical called serotonin, helps strengthen remaining nerve connections along the spine, giving patients with spinal cord injuries more ability to control their muscles during training. Continue Reading »
Data are sparse concerning the long-term effects of phosphodiesterase type 5 (PDE5) inhibitors for erectile dysfunction (ED).
To evaluate the efficacy and safety of long-term sildenafil use in subjects with ED caused by spinal cord injury (SCI). Continue Reading »
June 18, 2009 | Category: News
Those with spinal cord injuries, who have multiple sclerosis, or who’ve suffered a stroke are also often diagnosed with central pain syndrome.
It’s a harsh reality for people with debilitating conditions like spinal cord injury or stroke.
Many of them live with chronic, excruciating pain.
Kellye Lynn reports research is underway in Baltimore which could someday end the suffering for patients with central pain syndrome.
Patients who have the condition say it feels like being stabbed with a thousand burning knives. Continue Reading »
May 21, 2009 | Category: News
“Stem cell research and regenerative medicine are in an extremely exciting phase right now. We are gaining knowledge very fast and many companies are being formed and are starting clinical trials in different areas,” says Dr Jonas Frisén.
As an example, a first-in-human study was just initiated for Parkinson’s disease patients with the drug product, sNN0031, from the Swedish company NeuroNova. Continue Reading »
May 12, 2009 | Category: News
Transplanted embryonic stem cells are recognized as a potential treatment for patients suffering from the effects of spinal cord injury (SCI). However, in studies using embryonic stem cells transplanted into SCI laboratory animals, a serious drawback has been the development of tumors following transplantation.
Publishing in the current issue of Cell Transplantation (Vol. 18 No.1), a team of Japanese researchers describe their study that demonstrates a way to eliminate the problem of tumor growth by co-transplanting bone marrow stem cells (BMSCs) along with embryonic stem cells. Continue Reading »
The damage from primary and secondary insults of spinal cord injury can result in various hemodynamic alterations. It is important to understand the presentation and time course of these changes, in addition to the management of each, to avoid further clinical deterioration and complications.
Traumatic spinal cord injury has an incidence of 10,000 cases per year with a prevalence of approximately 200,000 people in the United States.1 These numbers do not account for deaths in the field, which are estimated to occur in 16% to 30% of these cases. The patient demographics mirror that of the general trauma population with the average age around 30 years and a male predominance. Although motor vehicle collisions account for roughly half of all spinal cord injury cases, other events including assaults, falls, work-place injuries, and sporting accidents account for a large portion of the rest.2
Pathophysiology Continue Reading »